Literature DB >> 23411061

Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Andrew R Haas1, Daniel H Sterman.   

Abstract

There is evidence that improved treatments of malignant pleural mesothelioma are increasing the quality and quantity of life for patients with mesothelioma. Multimodality treatment programs that combine maximal surgical cytoreduction with novel forms of radiation therapy and more effective chemotherapy combinations may offer significant increases in survival for certain subgroups of patients with mesothelioma. Lung-sparing surgery may allow improvements in pulmonary function after surgery-based multimodality therapy, and potential longer overall survival than that seen with extrapleural pneumonectomy. Experimental treatments provide hope for all patients with mesothelioma, and in the future may be combined with standard therapy in multimodality protocols.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23411061      PMCID: PMC3612173          DOI: 10.1016/j.ccm.2012.12.005

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  81 in total

Review 1.  Statement on malignant mesothelioma in the United Kingdom.

Authors: 
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.

Authors:  D J Sugarbaker; E C Heher; T H Lee; G Couper; S Mentzer; J M Corson; J J Collins; R Shemin; R Pugatch; L Weissman
Journal:  J Thorac Cardiovasc Surg       Date:  1991-07       Impact factor: 5.209

3.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

Authors:  D H Sterman; J Treat; L A Litzky; K M Amin; L Coonrod; K Molnar-Kimber; A Recio; L Knox; J M Wilson; S M Albelda; L R Kaiser
Journal:  Hum Gene Ther       Date:  1998-05-01       Impact factor: 5.695

4.  Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.

Authors:  C Boutin; J R Viallat; N Van Zandwijk; J T Douillard; J C Paillard; J C Guerin; P Mignot; J Migueres; F Varlet; A Jehan
Journal:  Cancer       Date:  1991-04-15       Impact factor: 6.860

5.  Trimodality management of malignant pleural mesothelioma.

Authors:  G Maggi; C Casadio; R Cianci; O Rena; E Ruffini
Journal:  Eur J Cardiothorac Surg       Date:  2001-03       Impact factor: 4.191

Review 6.  Malignant mesothelioma of the pleura.

Authors:  R J Pisani; T V Colby; D E Williams
Journal:  Mayo Clin Proc       Date:  1988-12       Impact factor: 7.616

7.  Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene.

Authors:  W R Smythe; H C Hwang; A A Elshami; K M Amin; S L Eck; B L Davidson; J M Wilson; L R Kaiser; S M Albelda
Journal:  Ann Surg       Date:  1995-07       Impact factor: 12.969

8.  Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.

Authors:  C Boutin; F Rey; J R Viallat
Journal:  Chest       Date:  1995-09       Impact factor: 9.410

9.  A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.

Authors:  Harvey I Pass; George J Brewer; Robert Dick; Michele Carbone; Sofia Merajver
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330

10.  Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies.

Authors:  O Monneuse; A C Beaujard; B Guibert; F N Gilly; P Mulsant; P Y Carry; M Benoit; O Glehen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more
  19 in total

1.  Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study.

Authors:  A Botticella; G Defraene; K Nackaerts; C Deroose; J Coolen; P Nafteux; B Vanstraelen; S Joosten; L A W Michiels; S Peeters; D De Ruysscher
Journal:  Strahlenther Onkol       Date:  2017-02-14       Impact factor: 3.621

2.  Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Authors:  Gregory T Kennedy; Brendan F Judy; Pratik Bhojnagarwala; Edmund K Moon; Zvi G Fridlender; Steven M Albelda; Sunil Singhal
Journal:  Immunol Lett       Date:  2015-05-18       Impact factor: 3.685

3.  "Lower door open thoracotomy": a feasible approach for extra-pleural pneumonectomy.

Authors:  Giovanni Leuzzi; Kenji Kawamukai; Calogero Porrello; Sergio Forti Parri; Gian Marco Guiducci; Nicola Lacava
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

4.  FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.

Authors:  E Incerti; S Broggi; A Fodor; M Cuzzocrea; A M Samanes Gajate; P Mapelli; C Fiorino; I Dell'Oca; M Pasetti; M Cattaneo; R Calandrino; L Gianolli; N Di Muzio; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

5.  Changing pattern in malignant mesothelioma survival.

Authors:  Jennifer Faig; Suzanne Howard; Edward A Levine; Gary Casselman; Mary Hesdorffer; Jill A Ohar
Journal:  Transl Oncol       Date:  2015-02       Impact factor: 4.243

6.  Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.

Authors:  Giulia Pinton; Arcangela G Manente; Antonio Daga; Michele Cilli; Maurizio Rinaldi; Stefan Nilsson; Laura Moro
Journal:  Mol Cancer       Date:  2014-10-02       Impact factor: 27.401

7.  Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.

Authors:  Arcangela G Manente; Giulia Pinton; Sara Zonca; Michele Cilli; Maurizio Rinaldi; Antonio Daga; Stefan Nilsson; Laura Moro
Journal:  Oncotarget       Date:  2015-09-22

8.  Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.

Authors:  Frances E Lennon; Gianguido C Cianci; Rajani Kanteti; Jacob J Riehm; Qudsia Arif; Valeriy A Poroyko; Eitan Lupovitch; Wickii Vigneswaran; Aliya Husain; Phetcharat Chen; James K Liao; Martin Sattler; Hedy L Kindler; Ravi Salgia
Journal:  Sci Rep       Date:  2016-04-15       Impact factor: 4.379

9.  Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.

Authors:  J Yamamoto; K Ohnuma; R Hatano; T Okamoto; E Komiya; H Yamazaki; S Iwata; N H Dang; K Aoe; T Kishimoto; T Yamada; C Morimoto
Journal:  Br J Cancer       Date:  2014-04-17       Impact factor: 7.640

10.  Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.

Authors:  Robin Cornelissen; Lysanne A Lievense; Alexander P Maat; Rudi W Hendriks; Henk C Hoogsteden; Ad J Bogers; Joost P Hegmans; Joachim G Aerts
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.